On the Record

"They're leaving out how they define a specialty drug in their formulary reporting, and that's really what payers want to know: the high-cost items — and is the formulary going to save me money?"

— Brian Anderson, a principal with Milliman, Inc., talked with AIS's RADAR on Drug Benefits about how PBMs are building their 2019 formularies, and transparency concerns payers may raise.